Therefore, the strength of the present study is that it is the first real-world large cohort study in Asia to investigate the risk of bladder cancer in patients on combination therapy of SGLT-2 inhibitors and Pio and the results showed neutral effects with short-term use. Here, SLC5A2 is linked to urinary bladder cancer.